Fact Sheet

Not a Moment to Lose: Critical Changes States Should Implement to Prevent Medicaid Coverage Losses

If states do not act, many of the over 88 million people who rely on Medicaid and the Children's Health Insurance Program (CHIP) for their health insurance could lose their coverage when the federal C...

New Protections from Unexpected Medical Bills: What You Need to Know about the No Surprises Act

On January 1, 2022, a new law went into effect that helps protect people from unexpected charges for some types of medical care. This law, the No Surprises Act, applies to people with health insurance...

Nuevas protecciones contra facturas médicas inesperadas: Lo que necesita saber sobre la Ley Sin Sorpresas

El 1 de enero de 2022, entró en vigencia una nueva ley que ayuda a proteger a las personas de cargos inesperados por algunos tipos de atención médica. Esta ley, la Ley Sin Sorpresas, se aplica a la...

The Time is Now for Administrative Action to Improve Medicare Dental Coverage

With millions of older adults and people with disabilities unable to afford the dental care they need to stay healthy, adding oral health coverage to Medicare is both much needed and in high demand. T...

Advancing Equity in 2022: Federal Policy Priorities to Promote Health Equity and Health System Transformation

Our nation must heed the lessons of the COVID-19 pandemic, which has taken a disproportionate toll on people of color and exposed painful but persistent truths about structural inequities in access to...

What Children and Families Need in Budget Reconciliation: Policy Recommendations to Improve Health and Well-Being

As Congress works to develop a robust budget reconciliation package, now is the time to ensure the inclusion of legislation that advances health equity and improves the health of parents and their chi...

Our Broken Drug Pricing and Patent System Diverts Resources Away from Innovation and into Mergers, Patent Gaming and Price Gouging

As Congress considers ways to reform drug pricing this year, it is, unsurprisingly, being met with heavy resistance from paid special interests, including pharmaceutical companies’ lawyers and lobby...